Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans
Dapagliflozin, a selective sodium–glucose co-transporter-2 inhibitor, and linagliptin, a competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed antidiabetic medications in general clinics. Since there are several merits to combining them in a fixed-dose combination product...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI AG
2022-03-01
|
| Serier: | Pharmaceutics |
| Fag: | |
| Online adgang: | https://www.mdpi.com/1999-4923/14/3/591 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
